NEW YORK, December 1, 2016 /PRNewswire/ --
Pre-market, Stock-Callers.com brings focus back on the global GenericDrugs industry, which, as per market research firm - Technavio, is anticipated to grow at a CAGR of more than 10% from 2016 to 2020. Additionally, competition is expected to increase in the coming years as a number of pharmaceutical drugs are set to
Shares in Hertfordshire, the UK-based Mylan N.V. ended Wednesday's session at $36.61, rising 1.53% from the last trading session. The stock recorded a trading volume of 5.52 million shares. The Company's shares have gained 0.30% in the last month. The stock is trading 3.38% below its 50-day moving average. Moreover, shares of Mylan, which together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide, have a Relative Strength Index (RSI) of 46.65.
On November 18th, 2016, research firm Mizuho reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $49 a share to $47 a share.
As per notes filed on November 29th, 2016 with the SEC, Mylan NV entered into a revolving credit agreement on November 22nd, 2016, among the Company, Mylan Inc., certain lenders and issuing banks and Bank of America, N.A. The New Senior Revolving Credit Agreement contains a revolving credit facility under which the Company may obtain extensions of credit in an aggregate principal amount not exceeding $2,000,000,000. Proceeds from the New Senior Revolving Facility will be used for working capital, capital expenditures, and other lawful corporate purposes. See our free and comprehensive research report on MYL at:
Dublin, Ireland headquartered Horizon Pharma PLC's stock saw a drop of 5.94%, closing the day at $19.80. A total volume of 5.14 million shares was traded, which was above their three months average volume of 3.03 million shares. The Company's shares have advanced 18.42% in the last month and 5.32% in the previous three months. The stock is trading 5.20% above its 50-day moving average and 10.53% above its 200-day moving average. Additionally, shares of Horizon Pharma, which engages in identifying, developing, acquiring, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the US and internationally, have an RSI of 49.74.
On November 14th, 2016, Horizon Pharma announced that a retrospective analysis of data from previous pivotal, randomized KRYSTEXXA® clinical trials demonstrate that refractory chronic gout patients defined as "non-responders" based on serum uric acid levels in the trials still achieved significant clinical benefit despite a loss of response in uric acid levels.
On November 28th, 2016, research firm Citigroup upgraded the Company's stock rating from 'Neutral' to 'Buy'. HZNP free research report PDF is just a click away at:
On Wednesday, shares in Dublin, Ireland headquartered Allergan PLC recorded a trading volume of 5.01 million shares, which was higher than their three months average volume of 4.58 million shares. The stock ended the day 0.86% higher at $194.30. The Company's shares are trading below their 50-day moving average by 10.96%. Furthermore, shares of Allergan, which develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide, have an RSI of 41.84.
On November 17th, 2016, research firm Mizuho reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $293 a share to $273 a share.
On November 22nd, 2016, Allergan announced that it has completed the acquisition of Chase Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company focused on the development of improved treatments for neurodegenerative disorders including Alzheimer's disease. Allergan acquired Chase for an upfront payment of $125 million and additional potential regulatory and sales milestone payments related to Chase's lead compound, CPC-201, and certain backup compounds. Sign up for your complimentary report on AGN at:
Somerset, New Jersey headquartered Catalent Inc.'s stock saw a slight decline of 0.75%, finishing yesterday's session at $23.93 with a total trading volume of 839,573 shares. The Company's shares have advanced 4.91% in the last one month. The stock is trading below its 50-day moving average by 3.26%. Additionally, shares of Catalent, which provides advanced delivery technologies and development solutions for drugs, biologics, and consumer health products worldwide, have an RSI of 41.46.
On November 28th, 2016, Catalent announced that its wholly owned subsidiary, Catalent Pharma Solutions, Inc., intends to offer, subject to market and other conditions, $400 million aggregate principal amount of euro-denominated senior unsecured notes due 2024 in a private offering. Register for free on Stock-Callers.com and download the latest research report on CTLT at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Find out about travel shots or vaccination before you travel to your destination country. Travel ...
Hay fever is caused by allergy to pollen and is characterized by runny or blocked nose, sneezing, ...
Therapeutic drug monitoring is measuring drug concentrations at specific intervals in a patient's ...View All